Wörwag Pharma is a medium-size family business created in 1965. The company is now operating in 40 countries and distributing products to over 104 international destinations, while managing to maintain the values of a family business. The future goals are determined by the basic philosophy: self-developed products and expertise, and OTC and generic medicines intended to enhance the well-being of patients.
For 40 years Wörwag Pharma stands for competence and expertise in the fields of biofactors and generics. We have established our reputation in Czech Republic and Slovakia as a specialist in the treatment of diabetes and its accompanying disorders.
Biofactors (vitamins and mineral supplements), preparations for polyneuropathy, and generics with excellent cost-benefit ratios: the broad product range of Wörwag Pharma. High quality medication, modern active substances and successful use of the medications in advanced therapeutic concepts in the fields of diabetic accompanying disorders confirm that Wörwag Pharma is an expert partner in science and practice.
Thinking and working globally is not a marketing strategy as far as we are concerned, but a way of living our profession every day – and it is at the same time, a challenge. Our task every day is to overcome long distances and cultural differences. With success!
Contact
Wörwag Pharma GmbH & Co. KG
Stolárska 35 – 831 06 Bratislava
Tel.: +421 (2) 44 88 99 20
Fax: +421 (2) 44 88 05 71
E-mail: info@woerwagpharma.sk
Wörwag Pharma GmbH & Co. KG
Bucharova 2657/12, Stodůlky – 158 00 Praha 5
Tel: +420 226 226 360
E-mail: info@woerwagpharma.cz
The latest pharma news from Central and Eastern Europe (CEE), including a new report on the disparities between the region’s healthcare systems and those of Western Europe; why US companies…
Roman Grunt, CEO of Quinta Analytica, gives us an overview of the activities of how the Czech firm has managed to attract customers across the country and beyond by positioning…
PharmaBoardroom’s latest report: Healthcare & Life Sciences Review: Czech Republic is available for download now. Home to a USD 3.38 billion pharma market, one of Central and Eastern Europe’s…
Key stakeholders within the Czech medtech industry highlight how medical devices can improve efficiency and quality of care across the country’s healthcare landscape, why greater levels of collaboration are of…
Roman Samiec, general manager of Thuasne Czech Republic, introduces the company as a key competitor in the medical devices field, with their niche products addressing the unmet medical need in…
Miroslav Palát, president of CzechMed, the medical device association in the Czech Republic, and Jiří Pavlíček, who combines the responsibility of Chairman of the association and CEO of the medtech…
Pavla Nevolová, country head of EastHORN in the Czech Republic, shares the historical roots of the now multinational Czech CRO. Nevolová also shares her insights into the recent evolution of…
The Czech Republic boasts a solid clinical research infrastructure and a supportive regulatory environment, meaning that it stands out as one of Central and Eastern Europe’s top destinations for clinical…
In 1996 Jiří Žák, chairman & current CEO of FARMAK, borrowed half a billion Czech crowns to take over a state-owned producer of vitamins for which he had started working…
As one of the few pharma companies in the Czech Republic to offer products across the whole healthcare spectrum, including prescription drugs, generics, over-the-counter (OTC) treatments, and food supplements, the…
Roman Dusil, GM of Pierre Fabre Laboratories in the Czech Republic and Slovakia, shares how the Czech affiliate is ahead of Pierre Fabre’s global transformation of the convergence between the dermo-cosmetic…
Pharma industry stakeholders are generally quick to suggest that the Czech Republic is one of the most over-regulated markets in Europe, with new or innovative therapies facing significant delays before…
See our Cookie Privacy Policy Here
